scholarly journals The metabolic syndrome and diabetes mellitus as predictors of thoracic aortic calcification as detected by non-contrast computed tomography in the Multi-Ethnic Study of Atherosclerosis

2015 ◽  
Vol 33 (7) ◽  
pp. 912-919 ◽  
Author(s):  
R. Katz ◽  
M. J. Budoff ◽  
K. D. O'Brien ◽  
N. D. Wong ◽  
K. Nasir
Keyword(s):  
Diabetes Mellitus ◽  
Computed Tomography ◽  
Metabolic Syndrome ◽  
Aortic Calcification ◽  
Ethnic Study ◽  
The Metabolic Syndrome ◽  
Thoracic Aortic Calcification

scholarly journals Relationship between coronary artery and descending thoracic aortic calcification as detected by computed tomography: The Multi-Ethnic Study of Atherosclerosis

2009 ◽  
Vol 204 (2) ◽  
pp. 440-446 ◽  
Author(s):  
Junichiro Takasu ◽  
Matthew J. Budoff ◽  
Kevin D. O’Brien ◽  
David M. Shavelle ◽  
Jeffrey L. Probstfield ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Coronary Artery ◽  
Aortic Calcification ◽  
Ethnic Study ◽  
Thoracic Aortic Calcification

scholarly journals Features of the Metabolic Syndrome and Diabetes Mellitus as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis

Circulation ◽  
2006 ◽  
Vol 113 (17) ◽  
pp. 2113-2119 ◽  
Author(s):  
Ronit Katz ◽  
Nathan D. Wong ◽  
Richard Kronmal ◽  
Junichiro Takasu ◽  
David M. Shavelle ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Aortic Valve ◽  
Aortic Valve Calcification ◽  
Valve Calcification ◽  
Ethnic Study ◽  
The Metabolic Syndrome

Inflammation and descending thoracic aortic calcification as detected by computed tomography: The Multi-Ethnic Study of Atherosclerosis

2008 ◽  
Vol 199 (1) ◽  
pp. 201-206 ◽  
Author(s):  
Junichiro Takasu ◽  
Ronit Katz ◽  
David M. Shavelle ◽  
Kevin O’Brien ◽  
SongShou Mao ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Aortic Calcification ◽  
Ethnic Study ◽  
Thoracic Aortic Calcification

Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

2017 ◽  
Vol 36 (1) ◽  
pp. 78-88 ◽  
Author(s):  
Christian Labenz ◽  
Vera Prenosil ◽  
Sandra Koch ◽  
Yvonne Huber ◽  
Jens U. Marquardt ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Hepatocellular Carcinoma ◽  
Metabolic Syndrome ◽  
Group Performance ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
Advanced Hepatocellular Carcinoma ◽  
Advanced Hcc ◽  
The Metabolic Syndrome ◽  
The Impact

Background/Aim: Individual components of the metabolic syndrome (MS) such as obesity or diabetes mellitus impair the prognosis of patients with hepatocellular carcinoma (HCC) following curative treatment approaches or transarterial therapies. The aim of this retrospective study was to assess the impact of these factors on the overall survival (OS) of patients with advanced HCC treated with sorafenib. Methods: Univariate and multivariate analyses were performed to assess the impact of individual components of the MS on the OS of 152 consecutive patients with advanced HCC treated with sorafenib. Results: The presence of overweight/obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, and of the MS itself did not impair the median OS. Multivariate analysis showed that Eastern Cooperative Oncology Group Performance Status ≥1 (hazards ratio [HR] 2.03), presence of macrovascular invasion (HR 1.71), Child-Pugh score B/C (HR 2.19), tumor grading G3 (HR 2.17), no prior HCC treatment (HR 2.34), and the presence of 2 or more out of 5 individual components of the MS (HR 0.65) were independent prognostic factors regarding the median OS. Conclusions: Our investigations do not confirm a negative prognostic role of individual components of the MS or the MS itself for patients with advanced HCC treated with sorafenib.

scholarly journals Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout

2020 ◽  
Vol 92 (5) ◽  
pp. 110-118 ◽  
Author(s):  
T. S. Panevin ◽  
M. S. Eliseev ◽  
M. V. Shestakova ◽  
E. L. Nasonov
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
New Drugs ◽  
Positive Effects ◽  
The Metabolic Syndrome ◽  
Sodium Glucose Cotransporter ◽  
The Russian Federation

Currently, only two drugs for reducing uric acid (UA), allopurinol and febuxostat, are registered in the Russian Federation, but their use does not allow to achieve the target level of UA in all cases. According to the results of numerous randomized trials, hyperuricemia and gout are associated with the corresponding components of the metabolic syndrome, including diabetes mellitus. The influence of factors is due to the need to search for new drugs that have a complex effect on several components of metabolic syndrome at once. Potentially attractive in this regard is a new group of drugs for the treatment of type 2 diabetes mellitus inhibitors of the sodium-glucose cotransporter of type 2, which, in addition to the main hypoglycemic actions, showed positive effects on the cardiovascular system, kidneys, as well as lowering UA.

Sign in / Sign up

Export Citation Format

Share Document